Scientific Concept of the National Cohort (status ... - Nationale Kohorte

More documents

Recommendations

Info

C.3 References 431. Statistisches Bundesamt, Methoden-Verfahren-Entwicklungen. Demographische Standards. Eine gemeinsame Empfehlung des Arbeitskreises Deutscher Markt und Sozialforschungsinstitute e. V. (ADM), der Arbeitsgemeinschaft Sozialwissenschaftlicher Institute e. V. (ASI) und des Statistischen Bundesamtes. 2004, Statistisches Bundesamt: Wiesbaden 432. Ahrens, W., B.M. Bellach, and K.H. Jöckel, Messung soziodemographischer Merkmale in der Epidemiologie. RKI-Schrift 1/98. 1998, München MMV Medizin Verlag. 433. Linos, E., et al., Atopy and risk of brain tumors: a meta-analysis. Journal of the National Cancer Institute, 2007. 99(20): p. 1544. 434. Wang, H. and T.L. Diepgen, Atopic dermatitis and cancer risk. British Journal of Dermatology, 2006. 154(2): p. 205-210. 435. Lloyd-Jones, D.M., et al., Parental cardiovascular disease as a risk factor for cardiovascular disease in middle-aged adults: a prospective study of parents and offspring. Jama, 2004. 291(18): p. 2204. 436. Rathmann, W., et al., Incidence of Type 2 diabetes in the elderly German population and the effect of clinical and lifestyle risk factors: KORA S4/F4 cohort study. Diabetic Medicine, 2009. 26(12): p. 1212-1219. 437. Wilson, P.W.F., et al., Prediction of incident diabetes mellitus in middle-aged adults: the Framingham Offspring Study. Archives of Internal Medicine, 2007. 167(10): p. 1068. 438. Coogan, P.F., J. Smith, and L. Rosenberg, Statin use and risk of colorectal cancer. Journal of the National Cancer Institute, 2007. 99(1): p. 32. 439. Friis, S., et al., Cancer risk among statin users: A population based cohort study. International Journal of Cancer, 2005. 114(4): p. 643-647. 440. Hoffmeister, M., J. Chang Claude, and H. Brenner, Individual and joint use of statins and low dose aspirin and risk of colorectal cancer: A population based case–control study. International Journal of Cancer, 2007. 121(6): p. 1325-1330. 441. Poynter, J.N., et al., Statins and the risk of colorectal cancer. New England Journal of Medicine, 2005. 352(21): p. 2184. 442. Shadman, M., et al., Non-steroidal anti-inflammatory drugs and statins in relation to colorectal cancer risk. World Journal of Gastroenterology: WJG, 2009. 15(19): p. 2336. 443. Döring, A., et al., KORA-Survey 2000. Manual of Operation. Untersucher- Handbuch. 2000, Neuherberg: GSF 444. Fricke, U., J. Günther, and A. Zawinell, Anatomisch-therapeutisch-chemische Klassifikation mit Tagesdosen für den deutschen Arzneimittelmarkt. Methodik der ATC-Klassifikation und DDD-festlegung. ATC-Index mit DDD-Angaben. GKV- Arzneimittelindex, 2005. 4. 445. Freedman, D.S., et al., The relation of menarcheal age to obesity in childhood and adulthood: the Bogalusa heart study. BMC pediatrics, 2003. 3(1): p. 3. 446. Kivimaki, M., et al., Association of age at menarche with cardiovascular risk factors, vascular structure, and function in adulthood: the Cardiovascular Risk in Young Finns study. American Journal of Clinical Nutrition, 2008. 87(6): p. 1876. 312
313 References 447. Lakshman, R., et al., Early age at menarche associated with cardiovascular disease and mortality. Journal of Clinical Endocrinology & Metabolism, 2009. 94(12): p. 4953. 448. Ensrud, K.E., et al., Frequency and severity of hot flashes and sleep disturbance in postmenopausal women with hot flashes. Menopause, 2009. 16(2): p. 286. 449. Joffe, H., et al., Vasomotor symptoms are associated with depression in perimenopausal women seeking primary care. Menopause, 2002. 9(6): p. 392. 450. International Agency for Research on Cancer, Combined Estrogen- Progestogen contraceptives and combined Estrogen-progestogen menopausal therapy, in IARC Monographs on the Evaluation of Carcinogenic Risks to Humans. 2007, IARC: Lyon. 451. Kemmeren, J.M., A. Algra, and D.E. Grobbee, Third generation oral contraceptives and risk of venous thrombosis: meta-analysis. Bmj, 2001. 323(7305): p. 131. 452. World Health Organization Collaborative Study of Cardiovascular Disease and Steroid Hormone Contraception, Effect of different progestagens in low oestrogen oral contraceptives on venous thromboembolic disease. Lancet, 1995. 346: p. 1582-1588. 453. Writing Group for the Women’s Health Initiative Investigators, Risks and benefits of estrogen plus progestin in healthy postmenopausal women: principal results from the Women's Health Initiative randomized controlled trial. Jama, 2002. 288(3): p. 321. 454. Roehrborn, C.G., Male lower urinary tract symptoms (LUTS) and benign prostatic hyperplasia (BPH). Med Clin North Am, 2011. 95(1): p. 87-100. 455. Verhamme, K.M.C., et al., Incidence and prevalence of lower urinary tract symptoms suggestive of benign prostatic hyperplasia in primary care--the Triumph project. European urology, 2002. 42(4): p. 323-328. 456. Bundesangentur für gesundheitliche Aufklärung, Die Drogenaffinität Jugendlicher in der Bundesrepublik Deutschland 2008. Alkohol-, Tabak-und Cannabiskonsum. Erste Ergebnisse zu aktuellen Entwicklungen und Trends. Köln: BZgA, 2008. 457. Hall, W., L. Degenhardt, and M. Teesson, Cannabis use and psychotic disorders: an update. Drug and Alcohol Review, 2004. 23(4): p. 433-443. 458. Kawohl, W. and W. Rössler, Cannabis and Schizophrenia: new findings in an old debate. Neuropsychiatrie: Klinik, Diagnostik, Therapie und Rehabilitation: Organ der Gesellschaft Österreichischer Nervenärzte und Psychiater, 2008. 22(4): p. 223. 459. Latza, U., W. Hoffmann, and C. Terschuren, Rauchen als möglicher Confounder in epidemiologischen Studien: Standardisierung der Erhebung, Quantifizierung und Analyse.[Smoking as potential confounder in German epidemiological studies: standardization of assessment, quantification, and analysis]. Gesundheitswesen, 2005. 67: p. 795-802. 460. Bischof, G., et al., Development and evaluation of a screening instrument for alcohol-use disorders and at-risk drinking: the brief alcohol screening instrument for medical care (BASIC). Journal of studies on alcohol and drugs, 2007. 68(4): p. 607. 461. Peasey, A., et al., Determinants of cardiovascular disease and other noncommunicable diseases in Central and Eastern Europe: rationale and design of the HAPIEE study. BMC Public Health, 2006. 6(1): p. 255. C.3
Page 1:
The National Cohort A prospective e
Page 4 and 5:
Applicants Applicants Applicants Cl
Page 6 and 7:
Applicants IV
Page 8 and 9:
Executive Summary 2. The National C
Page 10 and 11:
Executive Summary 3. Scientific aim
Page 12 and 13:
Executive Summary essary to address
Page 14 and 15:
Executive Summary 7. Examples for s
Page 16 and 17:
Contents A.2.4 major areas of expos
Page 18 and 19:
Contents A.3.8.2 Social security da
Page 20 and 21:
Contents A.6.4.2 Minimally detectab
Page 22 and 23:
Abbreviations C.2 mEThOdS fOr STATI
Page 24 and 25:
Abbreviations DXA Dual-energy x-ray
Page 26 and 27:
Abbreviations CHS Cardiovascular He
Page 28 and 29:
A.1 A.1 Introduction and overview a
Page 30 and 31:
A.1 A.1 Introduction and overview s
Page 32 and 33:
A.1 A.1 Introduction and overview T
Page 34 and 35:
A.1 A.1 Introduction and overview m
Page 36 and 37:
A.1 A.1 Introduction and overview
Page 38 and 39:
A.1 A.1 Introduction and overview s
Page 40 and 41:
A.1 A.1 Introduction and overview
Page 42 and 43:
A.1 A.1 Introduction and overview P
Page 44 and 45:
A.1 A.1 Introduction and overview t
Page 46 and 47:
A.1 A.1 Introduction and overview A
Page 48 and 49:
A.2 A.2. Scientific background and
Page 50 and 51:
Page 52 and 53:
Page 54 and 55:
Page 56 and 57:
Page 58 and 59:
Page 60 and 61:
Page 62 and 63:
Page 64 and 65:
Page 66 and 67:
Page 68 and 69:
Page 70 and 71:
Page 72 and 73:
Page 74 and 75:
Page 76 and 77:
Page 78 and 79:
Page 80 and 81:
Page 82 and 83:
A.3 A.3 Study design ment instrumen
Page 84 and 85:
A.3 A.3 Study design Table 3.2: Des
Page 86 and 87:
A.3 A.3 Study design Table 3.3: Dis
Page 88 and 89:
A.3 A.3 Study design the participan
Page 90 and 91:
A.3 A.3 Study design with a prepare
Page 92 and 93:
A.3 A.3 Study design rural areas, t
Page 94 and 95:
A.3 A.3 Study design A.3.2 Baseline
Page 96 and 97:
A.3 A.3 Study design Modules 70 Int
Page 98 and 99:
A.3 A.3 Study design ovarian carcin
Page 100 and 101:
A.3 A.3 Study design Table 3.5: Spe
Page 102 and 103:
A.3 A.3 Study design depression and
Page 104 and 105:
A.3 A.3 Study design to the extent
Page 106 and 107:
A.3 A.3 Study design ers to vaccina
Page 108 and 109:
A.3 A.3 Study design certain foods)
Page 110 and 111:
A.3 A.3 Study design A short instru
Page 112 and 113:
A.3 A.3 Study design ticipants and
Page 114 and 115:
A.3 A.3 Study design a resting time
Page 116 and 117:
A.3 A.3 Study design index, convent
Page 118 and 119:
A.3 A.3 Study design Although the i
Page 120 and 121:
A.3 A.3 Study design air and then t
Page 122 and 123:
A.3 A.3 Study design hemorrhages (0
Page 124 and 125:
A.3 A.3 Study design genetics of BM
Page 126 and 127:
A.3 A.3 Study design hand grip stre
Page 128 and 129:
A.3 A.3 Study design Project title
Page 130 and 131:
A.3 A.3 Study design diseases in va
Page 132 and 133:
A.3 A.3 Study design associations,
Page 134 and 135:
A.3 A.3 Study design Informed Conse
Page 136 and 137:
A.3 A.3 Study design 6. Since being
Page 138 and 139:
A.3 A.3 Study design the possible d
Page 140 and 141:
A.3 A.3 Study design A.3.5 Collecti
Page 142 and 143:
A.3 A.3 Study design Blood In addit
Page 144 and 145:
A.3 A.3 Study design the anterior n
Page 146 and 147:
A.3 A.3 Study design study. For exa
Page 148 and 149:
A.3 A.3 Study design large-size sto
Page 150 and 151:
A.3 A.3 Study design routinely prep
Page 152 and 153:
A.3 A.3 Study design Subjects who m
Page 154 and 155:
A.3 A.3 Study design A.3.6.3 reliab
Page 156 and 157:
A.3 A.3 Study design In addition, a
Page 158 and 159:
A.3 A.3 Study design Disease Questi
Page 160 and 161:
A.3 A.3 Study design Data routinely
Page 162 and 163:
A.3 A.3 Study design tial misclassi
Page 164 and 165:
A.3 A.3 Study design � The KORA c
Page 166 and 167:
A.3 A.3 Study design Table 3.16: Co
Page 168 and 169:
A.3 A.3 Study design Table 3.17: Co
Page 170 and 171:
A.4 A.4 Integrated Data Management
Page 172 and 173:
Page 174 and 175:
Page 176 and 177:
Page 178 and 179:
Page 180 and 181:
Page 182 and 183:
A.5 A.5 Methods for quality assuran
Page 184 and 185:
Page 186 and 187:
Page 188 and 189:
Page 190 and 191:
Page 192 and 193:
Page 194 and 195:
Page 196 and 197:
A.6 A.6 Planned statistical analyse
Page 198 and 199:
Page 200 and 201:
Page 202 and 203:
Page 204 and 205:
A.6 A.6 Table Planned 6.4: Expected
Page 206 and 207:
Page 208 and 209:
A.6 Planned statistical analyses an
Page 210 and 211:
Page 212 and 213:
Page 214 and 215:
Page 216 and 217:
Page 218 and 219:
A.7 A.7 Ethical aspects logical/gen
Page 220 and 221:
A.7 A.7 Ethical aspects The more ex
Page 222 and 223:
A.7 A.7 Ethical aspects pants, trav
Page 224 and 225:
A.7 A.7 Ethical aspects Data handli
Page 226 and 227:
A.7 Table 7.2 Availability of ident
Page 228 and 229:
A.7 A.7 Ethical aspects Should bios
Page 230 and 231:
A.7 A.7 Ethical aspects ing finding
Page 232 and 233:
A.7 A.7 Ethical aspects 206
Page 234 and 235:
C.1 C.1 Annex: Description of the s
Page 236 and 237:
Page 238 and 239:
Page 240 and 241:
Page 242 and 243:
Page 244 and 245:
Page 246 and 247:
Page 248 and 249:
Page 250 and 251:
Page 252 and 253:
Page 254 and 255:
Page 256 and 257:
Page 258 and 259:
C.1 C.1 Table Annex: 1: Cluster Des
Page 260 and 261:
Page 262 and 263:
Page 264 and 265:
Page 266 and 267:
Page 268 and 269:
Page 270 and 271: C.1 C.1 Annex: Description of the s
Page 282 and 283: C.2 C.2 Annex: Methods for Statisti
Page 286 and 287: C.2 Table S6.5: Sample size needed
Page 296 and 297: C.3 References 17. Keil, U., et al.
Page 298 and 299: C.3 References 50. Benjamin, E.J.,
Page 300 and 301: C.3 References 85. Calle, E.E. and
Page 302 and 303: C.3 References 121. Walter, R., D.J
Page 304 and 305: C.3 References 155. Ross, R., Ather
Page 306 and 307: C.3 References 189. Ghiotto, F., et
Page 308 and 309: C.3 References 225. Schmidt, C.O.,
Page 310 and 311: C.3 References 260. Eussen, S., et
Page 312 and 313: C.3 References 294. McCrae, R.R. an
Page 314 and 315: C.3 References 327. Lynch, J.W., G.
Page 316 and 317: C.3 References 360. Mair, C., A.V.
Page 318 and 319: C.3 References 395. Lesourd, B., Nu
Page 322 and 323: C.3 References 462. Bundeszentrale
Page 324 and 325: C.3 References 494. Rammstedt, B. a
Page 326 and 327: C.3 References 526. Mack, F., et al
Page 328 and 329: C.3 References 560. Palatini, P., A
Page 330 and 331: C.3 References 590. Greenland, P.,
Page 332 and 333: C.3 References 623. Olin, A.C., et
Page 334 and 335: C.3 References 658. Pate, R.R., J.R
Page 336 and 337: C.3 References 691. Zenge, M.O., et
Page 338 and 339: C.3 References 727. Ryu, O.H., et a
Page 340 and 341: C.3 References 757. BSI-Standard 10
Page 342 and 343: C.3 References 790. Davis, C.E., et
Page 344: C.3 References 822. Hegenscheid, K.
show all

Scientific Concept of the National Cohort (status ... - Nationale Kohorte

Create successful ePaper yourself

Delete template?

Save as template?